Meeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3514 Authors: Dung T. Le, Petr Kavan, Tae Won Kim, et. al. Background: Pembrolizumab is approved for the treatment of adult and pediatric patients (pts) with previously treated MSI-H cancer regardless of tumor type or site. This approval was based...
Pro zobrazení tohoto obsahu je třeba být přihlášen.